Ilenia Calcaterra: Innovation In Rare Diseases Is Never Abstract
Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared on LinkedIn, adding:
”Today is Rare Disease Day.
I work actively in the field of rare diseases, where progress often depends on rigorous research, multidisciplinary collaboration, and responsible clinical decision-making.
This image captures a milestone in our clinical practice: in September 2024, we administered the first gene therapy for Hemophilia A in our center.
Innovation in rare diseases is never abstract.
It is built carefully, through evidence, integrity, and high standards especially when patient numbers are small and every decision carries weight.
Raising awareness matters.
Building reliable evidence matters even more.
In rare diseases, small numbers require higher standards not lower ones.”
Stay updated with Hemostasis Today.
-
Sep 19, 2026, 01:53Thomas Dayspring: Understanding Genome and Lipid Interactions in Lipidology
-
Sep 19, 2026, 01:47Abdurrahman Tufan: Combination Targeted Therapy in Refractory Systemic Autoinflammatory Diseases
-
Sep 19, 2026, 01:44Patrick James Lynch: Mother of a Thousand Sons Premieres at BDC 2026
-
Sep 19, 2026, 01:41Genetic Fate Mapping Reveals Endothelial Cells During Venous Thrombus Resolution – RPTH Journal
-
Sep 19, 2026, 01:39Mostafa Hammam: Three Different Platelet Defects – One Common Symptom
-
Sep 19, 2026, 01:38Jeff Sternlicht: A Heart Attack Should Not Be the Starting Line
-
Sep 19, 2026, 01:28Luis Oliverio Ambriz Garcia: Key Points From the ASH 2026 Guidelines on Iron Deficiency
-
Sep 19, 2026, 01:27Farjah Algahtani: A New Era in the Treatment of Transfusion-Dependent Thalassaemia
-
Sep 19, 2026, 01:24Aravind Palraj: 2025 EULAR Behçet’s Syndrome Update – 5 Practical Take-Home Points